Research Article
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes
Table 1
Baseline characteristics, ticagrelor, and prasugrel compared to clopidogrel.
| | Characteristics | Clopidogrel (n = 14407) | Ticagrelor (n = 568) | | Prasugrel (n = 501) | |
| | Demographics | | Age | 66.5 ± 12.0 | 61.3 ± 11.7 | <0.001 | 58.1 ± 10.5 | <0.001 | | Female gender | 4036 (28.0) | 130 (22.9) | 0.01 | 97 (19.4) | <0.001 | | Race | | | 0.03 | | 0.09 | | White | 9592 (66.6) | 378 (66.5) | | 318 (63.5) | | | Black | 866 (6.0) | 20 (3.5) | | 28 (5.6) | | | Asian | 2542 (17.6) | 101 (17.8) | | 89 (17.8) | | | Other/unknown | 1407 (9.8) | 69 (12.2) | | 66 (13.1) | | | Hispanic ethnicity | 1813 (12.6) | 378 (66.5) | 0.35 | 69 (13.8) | 0.43 | | Cardiovascular history | | Prior MI | 3161 (21.9) | 86 (15.1) | <0.001 | 117 (23.4) | 0.45 | | Prior CABG | 1627 (11.3) | 30 (5.3) | <0.001 | 30 (6.0) | <0.001 | | Cerebrovascular disease | 1220 (8.5) | 25 (4.4) | 0.001 | 7 (1.4) | <0.001 | | Peripheral vascular disease | 5573 (38.7) | 137 (24.1) | <0.001 | 105 (21.0) | <0.001 | | Heart failure | 3121 (21.7) | 80 (14.1) | <0.001 | 76 (15.2) | <0.001 | | Atrial fibrillation | 1618 (11.2) | 23 (4.0) | <0.001 | 22 (4.4) | <0.001 | | Hyperlipidemia | 9889 (68.6) | 305 (53.7) | <0.001 | 281 (56.1) | <0.001 | | Hypertension | 10828 (75.2) | 358 (63.0) | <0.001 | 321 (64.1) | <0.001 | | Diabetes | 5069 (35.2) | 176 (31.0) | 0.04 | 137 (27.3) | <0.001 | | Other risk factors | | Smoking | | | <0.001 | | <0.001 | | Previous | 5632 (39.1) | 166 (29.2) | | 166 (33.1) | | | Current | 1848 (12.8) | 88 (15.5) | | 95 (19.0) | | | No/unknown | 6927 (48.1) | 314 (55.3) | | 240 (47.9) | | | Chronic kidney disease | 3627 (25.2) | 86 (15.1) | <0.001 | 74 (14.8) | <0.001 | | Chronic lung disease | 1429 (9.9) | 44 (7.7) | 0.09 | 36 (7.2) | 0.04 | | Dialysis | 412 (2.9) | 8 (1.4) | 0.04 | 5 (1.0) | 0.01 | | Dyslipidemia | 11380 (79.0) | 401 (70.6) | <0.001 | 362 (72.3) | <0.001 | | Family history of premature CAD | 1888 (13.1) | 87 (15.3) | 0.13 | 93 (18.6) | <0.001 | | Liver disease | 1101 (7.6) | 35 (6.2) | 0.19 | 37 (7.4) | 0.83 | | Laboratory data | | Creatinine | 1.1 ± 1.0 | 1.1 ± 1.0 | 0.84 | 1.0 ± 0.7 | <0.001 | | Hemoglobin | 13.4 ± 1.9 | 14.3 ± 1.8 | <0.001 | 14.1 ± 1.8 | <0.001 | | Platelets | 216.1 ± 68.9 | 234.8 ± 65.3 | <0.001 | 226.5 ± 79.9 | 0.01 | | Sodium | 138.4 ± 3.2 | 138.0 ± 3.0 | 0.01 | 139.1 ± 3.2 | <0.001 | | WBC count | 8.6 ± 3.7 | 9.6 ± 3.1 | <0.001 | 9.4 ± 3.4 | <0.001 | | Procedure details | | PCI indication | | | <0.001 | | <0.001 | | NSTEMI/unstable angina | 11520 (80.0) | 285 (50.2) | | 297 (59.3) | | | STEMI | 2887 (20.0) | 283 (49.8) | | 204 (40.7) | | | Bare metal stent | 685 (4.8) | 8 (1.4) | <0.001 | 19 (3.8) | 0.32 | | Drug eluting stent | 13149 (91.3) | 543 (95.6) | <0.001 | 469 (93.6) | 0.07 | | Thrombectomy | 807 (5.6) | 33 (5.8) | 0.83 | 70 (14.0) | <0.001 | | Bifurcation lesion | 3123 (21.7) | 54 (9.5) | <0.001 | 99 (19.8) | 0.31 | | Lesion complexity | | | 0.49 | | 0.06 | | High/C | 7643 (53.1) | 293 (51.6) | | 287 (57.3) | | | Nonhigh/non-C | 6764 (46.9) | 275 (48.4) | | 214 (42.7) | | | Previously treated lesion | 750 (5.2) | 25 (4.4) | 0.40 | 53 (10.6) | <0.001 | | Vein graft PCI | 594 (4.1) | 12 (2.1) | 0.02 | 12 (2.4) | 0.05 | | Cardiac arrest within 24 hours | 226 (1.6) | 12 (2.1) | 0.31 | 17 (3.4) | 0.002 | | Cardiomyopathy or LV systolic dysfunction | 1700 (11.8) | 18 (3.2) | <0.001 | 36 (7.2) | 0.002 | | Cardiogenic shock within 24 hours | 206 (1.6) | 12 (3.2) | 0.01 | 14 (2.9) | 0.02 | | Stress test | 3511 (24.4) | 84 (14.8) | <0.001 | 100 (20.0) | 0.02 | | Arterial access site | | | <0.001 | | <0.001 | | Brachial | 17 (0.1) | 0 (0.0) | | 1 (0.2) | | | Femoral | 8049 (55.9) | 125 (22.0) | | 335 (66.9) | | | Radial | 6334 (44.0) | 442 (77.8) | | 165 (32.9) | | | Other | 7 (0.0) | 1 (0.2) | | 0 (0.0) | | | Fluoroscopy time | 17.7 ± 13.1 | 16.8 ± 11.9 | 0.07 | 18.7 ± 15.0 | 0.12 | | Contrast volume (ml) | 178.9 ± 82.0 | 163.6 ± 67.1 | <0.001 | 213.1 ± 99.3 | <0.001 | | Lesion length | 29.3 ± 21.3 | 31.2 ± 20.2 | 0.04 | 31.1 ± 23.0 | 0.08 | | Risk score | | Precise DAPT score | 27.7 ± 19.3 | 18.4 ± 13.6 | <0.001 | 18.7 ± 16.1 | <0.001 | | Medication use post PCI | | ACE inhibitors | 8872 (61.6) | 406 (71.5) | <0.001 | 351 (70.1) | <0.001 | | ARBs | 3680 (25.5) | 139 (24.5) | 0.57 | 101 (20.2) | 0.01 | | Oral anticoagulation | 1541 (10.7) | 22 (3.9) | <0.001 | 30 (6.0) | <0.001 | | Beta blockers | 13532 (93.9) | 542 (95.4) | 0.14 | 477 (95.2) | 0.24 | | Statins | 13983 (97.1) | 557 (98.1) | 0.16 | 490 (97.8) | 0.33 |
|
|
MI, myocardial infarction; CABG, coronary artery bypass graft; CAD, coronary artery disease; WBC, white blood cell; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; ACE inhibitors, angiotensin-converting enzyme inhibitors; and ARBs, angiotensin II receptor blockers.
|
